Feb 4, 2026
•
9 min read
Federal strategy shifts from mRNA to oral antivirals • Monthly GLP-1 hits 10–12% vs. 15%+ bar • Quest MRD disrupts bone marrow biopsies
Feb 3, 2026
8 min read
PreCheck applications now open. Venglustat wins Gaucher, misses Fabry.
Feb 2, 2026
7 min read
Originating site restrictions return. AZ pays $1.2B upfront for monthly obesity dosing platform.
Jan 30, 2026
GRAIL's multi-cancer test PMA filed • Formation's $500M autoimmune buy • RFK Jr. revamps Alzheimer's priorities • Oracle's AI data launch
Cell therapy manufacturing pivots to scale, Quadruplet myeloma becomes standard, AAV safety pressure rises
UnitedHealth crashes on MA rate shock & guidance cut; Intellia clears partial CRISPR hold; Resonetics M&A and Boston Scientific updates inside.
Sarepta’s 3-year durability resets gene therapy risk, UnitedHealth earnings frame utilization pressure, FDA tightens MRD expectations.
Why milestone-heavy deals, AI workflows, and payer rules now shape execution risk.
Janux secures $850M BMS deal; Corxel raises $287M for oral obesity; Mendra launches with $82M.
FDA drafts MRD guidance for myeloma; IntraBio hits Phase 3 endpoints; BioCryst/Astria merger set to close.
Gedatolisib earns Priority Review with a July 17 PDUFA date; Worldwide acquires Catalyst amid CRO consolidation. Plus oncology updates and J&J earnings to watch.
Absorbing Friday’s Ionis, Blueprint, and Krystal raises, plus what to watch ahead of J&J’s Q4 print on Stelara erosion and MedTech recovery.
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
